Previous close | 0.0700 |
Open | 0.0700 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 5.00 |
Expiry date | 2024-06-21 |
Day's range | 0.0700 - 0.0700 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Explore key insights from Acumen Pharmaceuticals' Q1 2024 earnings, focusing on their innovative Alzheimer's treatments and financial outlook.
Q1 2024 Acumen Pharmaceuticals Inc Earnings Call
Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in May 2024Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024Cash, cash equivalents and marketable securities of $296.6 million as of Mar. 31, 2024, expected to support current clinical and operational activities into the first half of 2027Company to host conference call and webcast today at 8:00 a.m. ET CHAR